stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) Net margin
GeneDx Holdings Corp.'s net margin over the twelve months to 30 June 2026 was −23.4%, down 18.5 percentage points from fiscal 2025 (−4.92%). Over the past ten years it has ranged from −233.9% (fiscal 2022) to −4.92% (fiscal 2025) — the current reading is the highest in ten years. That is below the Diagnostics & Research industry median of −4.10% and below the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | −4.92% | 12.20 |
| FY2024 | −17.1% | 69.65 |
| FY2023 | −86.8% | 147.14 |
| FY2022 | −233.9% | (118.27) |
| FY2021 | −115.6% | 18.94 |
| FY2020 | −134.6% | (117.89) |
| FY2019 | −16.7% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | −15.5% | 46.42 |
| Mar 2026 | −61.9% | (47.32) |
| Dec 2025 | −14.6% | (8.06) |
| Sep 2025 | −6.54% | (17.07) |
| 20 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| CDNA CareDx, Inc. compare | 25.9% |
| VCYT Veracyte, Inc. compare | 21.8% |
| FRNM Freenome, Inc compare | 0.00% |
| NEO NeoGenomics, Inc. compare | −4.10% |
| CSTL Castle Biosciences, Inc. compare | −6.10% |
| WGS GeneDx Holdings Corp. | −23.4% |
| ADPT Adaptive Biotechnologies Corporation compare | −23.7% |
| OPK OPKO Health, Inc. compare | −29.5% |
| PSNL Personalis, Inc. compare | −147.7% |
| Diagnostics & Research industry median | −4.10% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on WGS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement